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M A J O R A R T I C L E
High Frequency, Sustained T Cell Responses to
PARV4 Suggest Viral Persistence In Vivo
Ruth Simmons,1 Colin Sharp,3 Stuart Sims,3 Henrik Kloverpris,2 Philip Goulder,2 Peter Simmonds,3 Paul Bowness,4,5 and
Paul Klenerman1,5
1Nuffield Department of Medicine, 2Department of Pediatrics, University of Oxford, Peter Medawar Building for Pathogen Research, United Kingdom;
3University of Edinburgh, Centre for Infectious Diseases, United Kingdom; 4Weatherall Institute of Molecular Medicine and 5National Institute for
Health Research Biomedical Research Centre, John Radcliffe Hospital, Oxford, United Kingdom
Background. Parvovirus 4 (PARV4) is a recently identified human virus that has been found in livers of patients
infected with hepatitis C virus (HCV) and in bone marrow of individuals infected with human immunodeficiency
virus (HIV). T cells are important in controlling viruses but may also contribute to disease pathogenesis. The
interaction of PARV4 with the cellular immune system has not been described. Consequently, we investigated
whether T cell responses to PARV4 could be detected in individuals exposed to blood-borne viruses.
Methods. Interferon c (IFN-c) enzyme-linked immunospot assay, intracellular cytokine staining, and a
tetrameric HLA-A*0201–peptide complex were used to define the lymphocyte populations responding to PARV4
NS peptides in 88 HCV-positive and 13 HIV-positive individuals. Antibody responses were tested using a recently
developed PARV4 enzyme-linked immunosorbent assay.
Results. High-frequency T cell responses against multiple PARV4 NS peptides and antibodies were observed in
26% of individuals. Typical responses to the NS pools were.1000 spot-forming units per million peripheral blood
mononuclear cells.
Conclusions. PARV4 infection is common in individuals exposed to blood-borne viruses and elicits strong
T cell responses, a feature typically associated with persistent, contained infections such as cytomegalovirus.
Persistence of PARV4 viral antigen in tissue in HCV-positive and HIV-positive individuals and/or the associated
activated antiviral T cell response may contribute to disease pathogenesis.
There are 4 parvoviruses known to infect humans:
adeno-associated virus, human bocavirus, B19, and
parvovirus 4 (PARV4) [1]. PARV4 was first identified
in 2005 in an injecting drug user (IDU) with acute
onset of symptoms including fatigue, vomiting,
arthralgias, and confusion [2]. PARV4 has been found
in the livers of 7/18 advanced hepatitis C virus
(HCV)–positive patients [3] and in the bone marrow
of 31/58 human immunodeficiency virus (HIV)–
positive individuals [4, 5].
PARV4 has a 5 kb linear genome of single-stranded
DNA that contains 2 open reading frames (ORFs): ORF1
and ORF2 are genetically and likely functionally
homologous to NS and VP proteins, respectively, in
other parvoviruses. They share greatest nucleotide
identity (85%) with a chimpanzee variant recently found
in Cameroon [6] but are also similar to parvoviruses in
wild boars, pigs, and cows (porcine and bovine
hokovirus) [7, 8]. These sequence relationships likely
justify the classification of these viruses into a new genus.
PARV4 has 3 known genotypes: genotypes 1 and 2 are
found mainly in Western countries, whereas genotype 3
has only been detected in sub-Saharan Africa [9–12].
Most studies to date have looked for the presence of
viral DNA in various populations. PARV4 DNA has
been detected in 0–5% of healthy blood donors in 8
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studies (median: 1%) [13–20] and in up to 85% of IDU HIV-
positive individuals with AIDS [15]. The frequency of co-
infection with HCV has varied from 8% to 30% [15, 20, 21]. A
recently developed enzyme-linked immunosorbent assay (ELI-
SA) has allowed the comparison between DNA detection, which
is rarely positive in peripheral blood, and the presence of anti-
bodies to PARV4 [18]. Thirty-three percent of HCV-positive
individuals and 67% of HIV/HCV-coinfected individuals were
seropositive. It has been suggested that frequent coinfection of
PARV4 in HIV- and HCV-positive individuals is due to a shared
transmission route [15]. Parenteral transmission is supported by
the high prevalence of PARV4 DNA and antibodies in hemo-
philiacs [15, 18] and the relatively low prevalence in non-IDU
men who have sex with men (MSM) [18]. Nonetheless, low
frequencies of seropositivity are found among these HCV-neg-
ative MSM. Additionally, high incidence of PARV4 infection has
been described in healthy infants from Ghana [9], in the general
population in Central Africa, and in HIV-1–positive individuals
without parenteral risk factors [10, 22], suggesting alternative
transmission routes.
The T cell immune response plays a major role in viral
clearance, for example, in HCV [23]. Previous studies on
parvovirus B19, a more common human infection, have
shown that this family of viruses can trigger surprisingly
strong and long-lived cellular responses (900 spot-forming
units per million peripheral blood mononuclear cells [SFU/
106 PBMCs] per pool of 10 peptides, detected up to 32 months
after onset of symptoms) especially to the nonstructural
protein NS1 of B19 [24, 25].
In view of the importance of cellular immunity in controlling
infection, and since the T cell immune response to PARV4 has
not been studied previously, we investigated whether HCV- and
HIV-positive individuals made such a response. Stimulated
T cells produce interferon c (IFN-c) as part of the antiviral
response, and this cytokine can be detected using enzyme-linked
immunospot (ELISpot) assays to measure magnitude and spe-
cificity. We present here the first data on the breadth,
magnitude, specificity, and phenotype of the T cell responses to
PARV4.
METHODS
Study Subjects and Sample Collection
Informed patient consent was obtained from 4 groups of in-
dividuals: 88 HCV-positive (HIV-negative) individuals (Sup-
plementary Table), 13HIV-positive (HCV-negative) individuals,
7 acute B19-seropositive (immunoglobulin M [IgM]) in-
dividuals, and 9 healthy individuals for control tests (local ethical
approvals: COREC O4.OXA.010, 06/Q1604/2, and CO2.113).
Blood samples were obtained while patients were not under-
going HCV treatment (except for one patient, with no PARV4-
specific response); of those previously treated (43/88), samples
were a minimum of 5 months post-treatment (range: 5–77
months, median: 25). PBMCs were obtained from heparinized
blood by density gradient centrifugation and were either tested
directly or frozen until needed.
Synthetic Peptides
One hundred thirty-one peptides of 15 amino acids in length,
overlapping by 10 amino acids spanning the entire PARV4 NS
protein of the prototype genotype 1 sequence (AY622943), were
synthesized (.70% pure, fluorenylmethyloxycarbonyl chem-
istry [Weatherall Institute of Molecular Medicine, Oxford]),
weighed, and dissolved in dimethyl sulfoxide (DMSO [Sigma]).
These were combined into 13 pools of 10 peptides each.
IFN-g ELISpot Assays
ELISpot assays were carried out ex vivo unless mentioned, with
PARV4 NS pools and individual peptides as described elsewhere
[26]. Then 23 105 PBMCs were plated per well in duplicate and
incubated overnight at 37C, 5% CO2, with peptides at 1 lmol/L.
Wells containing PBMCs with DMSO or concavidin A (20 lg/mL
[Sigma]) were used as negative or positive controls, respectively.
The plates were read on an automated ELISpot reader (AID), and
results were presented as SFU/106 PBMCs. A well was considered
positive if above 55 SFU/million PBMC per pool of peptides after
subtraction against the average of duplicate background wells.
This cutoff has been extensively evaluated using negative controls
in ongoing vaccine trials in our group [27] and in HIV ELISpots
[28]. This value is also above both the mean value 13 standard
deviations (5 14) and the highest count seen in the controls of
this study (healthy and B19-positive individuals).
Serological Screening
Serum samples from 84 of 88 individuals were tested for anti-
PARV4 immunoglobulin G (IgG; and additionally IgM in a
subset) as described elsewhere [18].
PBMC Culture
PBMCs were pulsed with 25 lmol/L peptide for 30 minutes
before incubating at 37C, 5% CO2, for 10–14 days, supple-
menting every 3 days with natural human T cell growth factor
(10% vol/vol [Helvetica Healthcare]). Cells were harvested
and assayed by intracellular cytokine staining (ICS). After 14
days of culture, PBMCs could be maintained with HLA-
matched B cell lines (BCL) pulsed with PARV4 peptide (12.5
lmol/L for 1 h at 37C) and 3 healthy donor PBMCs to use
as feeders. BCLs and healthy PBMCs were irradiated with 30
Gy. Cells were resuspended with the individual PBMCs to
culture at a 1:1 ratio.
Intracellular Cytokine Staining, Surface Staining, and Flow
Cytometry Analysis
Cells were counted and aliquoted at106 per condition. Negative
and positive controls were set up with DMSO and with phorbol
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myristate acetate (.05 lg/mL [Sigma]) and ionomycin (.5 lg/mL
[Sigma]), respectively. Samples were stimulated with 3 lmol/L
peptide. Then 2 lg/mL brefeldin A (Sigma) was added to each
tube, and they were incubated at 37C, 5% CO2, for 5–6 h. Cells
were surface stained with fluorochrome-conjugated antibodies
and processed for analysis or, for ICS, were permeabilized
(BD Cytofix/Cytoperm) and then stained for intracellular
markers for Fluorescence-Activated Cell Sorting (FACS) anal-
ysis. Fluorochrome-conjugated antibodies used were live/dead
marker L34955, CD4-QDot 605 (Invitrogen), CD8-APC, CD8-
PE-Cy7, IFNc–Alexa Fluor 700, CCR7-PE-Cy7 (BDPharmin-
gen), CD8-PerCP-Cy5.5, IFNc–FITC (BD Biosciences), CD45
RA-APC (AbCam), and HLA-A*0201-RMT-PE tetramer
(synthesized as described elsewhere [29]). All samples were
processed on a BD LSR II and analyzed using FlowJo software.
Lymphocytes were gated on forward and side scatter, and
then live CD31 cells were gated. The FACS plots presented in
this study are gated on CD31 cells uness indicated.
Figure 1. Analysis of PARV4 T cell responses in HCV-infected patients and controls. T cell responses were assessed by IFN-c ELISpot assays with
PARV4 NS peptides. (A) T cells from 88 HCV-infected patients to each peptide pool are summed so that each column represents the response of one
patient to the entire NS protein. (B) These photos of ELISpot wells are examples of the highest levels of responses and their negative control wells
(DMSO). Peptide pool responses for patients 117 and 425 are 410 and 248 SFU/well, respectively. (C–D) These graphs show the distribution and the
magnitude of the T cell responses across the NS protein. (C) Each column represents the number of patients responding to each pool. These are
concentrated at the N-terminus of the protein. (D) Each column represents the range of responses of all responders and the median to that peptide pool.
PARV4 NS responders indicate preferential recognition of N-terminal pools of peptides. (E–F) T cell responses of 9 healthy individuals (E) and 7 B19-
positive patients (F) to PARV4 NS peptide pools are displayed. Each point represents the T cell response of one individual to the peptide pool on the x-axis.
The highest response was 35 SFU/106 PBMC. The dashed line marks the cutoff for positivity.
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DNA Extraction and HLA Typing
DNA was extracted using the Gentra Puregene kit (Qiagen) from
PBMCs or from whole blood, as described by the manufacturer.
HLA typing was performed using the Sequence-Specific Primer
method (Weatherall Institute of Molecular Medicine, Oxford) [30].
Epitope Prediction
Bioinformatics programs Syfpeithi (http://www.syfpeithi.de) and
Bimas (http://www-bimas.cit.nih.gov/molbio/hla_bind/) were
used to predict potential epitopes. These were recorded if their
score was above 20 for Syfpeithi and above 50 for Bimas. The
peptide RMTENIVEV identified through experiments was a 9
amino acid epitope that scored 27 in Syfpeithi and 474 in Bimas.
Statistics
Statistics were calculated using the Mann-Whitney test and
Fisher exact test using GraphPad Prism software.
RESULTS
HCV-Positive Individuals Have Strong T Cell Responses to
PARV4 NS Peptides That Are Maintained Over Time
PBMCs from 88 randomly selected HCV-positive individuals at-
tending a hospital as outpatients, 9 healthy individuals, and 7
individuals with acute parvovirus B19 infection were assayed by
ELISpot for the production of IFN-c in response to 13 pools of 10
PARV4 NS peptides. Summed responses of all HCV-positive in-
dividuals to the entire NS protein are shown in Figure 1A.
Twenty-three HCV-positive individuals (26%) had T cell re-
sponses to individual pools higher than the predefined cutoff 55
SFU/106 PBMC (seeMethods), and 18 had T cell responses higher
than 250 SFU/106 PBMC, with a maximum of 2045 SFU/106
PBMC per peptide pool (Figure 1C–1D). Examples of the highest
responses seen in this assay are presented in Figure 1B. PBMC
samples from one time point were also confirmed in other assays
such as ICS (see below). Additionally, a selection of responders in
the cohort were tested longitudinally: 6/7 individuals with positive
responses remained positive across periods of 3 months to 3 years
(Table 1 and Figure 2). The T cell response of the 7th individual
was recovered upon culture of the PBMCs with peptide (data not
shown). Likewise, 3/3 individuals with no response remained
negative over time. Responses to the N-terminal portion of the NS
protein were both higher in magnitude and more frequent (pools
1–7: 37 responses, median: 6; pools 8–13: 9 responses, median: 1.5;
Mann-Whitney test, P5 .036; Figures 1C–1D). Some individuals
with T cell responses to pools were tested against individual
peptides; in total, 13 individual peptides were identified (data not
shown and see below).
As controls, 9 healthy ‘‘low-risk’’ individuals were tested; the
maximum median of all individuals for one single pool was 3.75
SFU/106 PBMC, with responses reaching a maximum of 35 SFU/
106 PBMC per peptide pool (ie, under the predefined cutoff
[Figure 1E]). Seven individuals with acute parvovirus B19 in-
fection also had low responses, with a maximum median of all
individuals for one single pool of 6.25 SFU/106 PBMC and an
individual maximum of 30 SFU/106 PBMC (Figure 1F). The T cell
responses of healthy controls and individuals with acute B19 in-
fection did not differ significantly (Mann-Whitney test, P5 .61).
Analysis of Antibody Responses in Relation to T Cell Responses
Serum samples from 84 of 88 HCV-positive individuals and 12
of 16 control individuals (5 B19 positive and 7 healthy) were
available for serological tests. Anti-PARV4 antibodies were
found in 22 HCV-positive individuals (26% seroprevalence) and
in no control individuals. Fourteen individuals had both anti-
bodies and T cell responses, 7 showed T cell responses but were
seronegative, 8 were seropositive for PARV4 antibodies, and 55
had neither (data not shown). To investigate the frequent dis-
crepancies in T cell and serological reactivity, we repeated and
retested antibody levels and T cell responses at several time points.
For example, individual 117 was tested for antibodies on serum
samples from 2 time points, and both were negative. On the other
hand, PBMC samples from these same time points were both
positive and at very high levels (2045 and 1890 SFU/million
PBMC per peptide pool [Figure 2, antibody data not shown]).
These 7 individuals lacking anti-PARV4 IgG were also negative in
an additional ELISA for anti-PARV4 IgM. Overall, the correlation
between T cell responses and IgG detection was significant (Fisher
exact test, P, .0001), although clearly individuals may possess T
cell responses without detectable antibody and vice versa.
HIV-Positive Individuals Elicit a Similar Rate of Response as the
HCV-Positive Individuals
We next investigated whether T cell responses to PARV4 could
be detected in individuals with another persistent infection. We
studied 13 HIV-positive HCV-negative individuals for IFN-c
Table 1. T Cell Responses to PARV4 Are Maintained Over Time
Patient No.
First Time Point Second Time Point
Sample Date Result Sample Date Result
117 Feb-06 1 Feb-09 1
123 Oct-06 2 Nov-09 2
146 Jul-08 1 Oct-09 1
162 Feb-06 2 May-09 2
289 Mar-07 2 May-09 2
324 Oct-06 1 Nov-09 2
382 Apr-07 1 Nov-09 1
422 Apr-08 1 Oct-08 1
433 Feb-08 1 May-08 1
457 Dec-08 1 Feb-10 1
NOTE. A positive response (1) is defined by at least 1 pool eliciting a T cell
response .55 SFU/106 PBMC. Only the response of patient 324 was not
detectable ex vivo at the second time point (data not shown). –, the absence of
response.
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production in response to PARV4 NS. Figure 3 shows that T cell
responses were detected at a comparable frequency and level to
the HCV cohort; 3 individuals had responses over 55 SFU/106
PBMC per peptide pool. This figure shows that, as in HCV-
positive individuals, the responses targeted the N-terminal half
of the NS protein. Anti-PARV4 antibodies were detected in 2/13
HIV-positive individuals, only one of whom also demonstrated
a T cell response to PARV4 peptides. Thus, an immune response
to PARV4 was detectable in HIV-positive individuals and
comparable to those in the HCV-positive cohort.
Identification of PARV4-Specific CD81 T Cells and an
HLA-A*0201–Restricted PARV4 Epitope RMTENIVEV
The nature of the T cell immune response to PARV4 peptides
was further characterized through ICS assays. Due to restricted
PBMC samples, not all individuals could be tested. Figure 4
Figure 2. Longitudinal analysis of T cell responses to PARV4 NS. T cell responses of patients 117 (A) and 457 (B) are illustrated here as examples of
sustained responses over time. The dates next to the patient numbers represent the sample date. (''457 june 2008'' sample: these cells were cultured
with peptide for 22 days before the assay.) OLP, overlapping peptides.
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shows that CD81 T cells produced IFN-c in response to PARV4
NS peptides in 2 individuals. Individual 314 made a strong
CD81 T cell response to NS pools 2 and 3, constituting 2.8% of
total CD81 T cells. Individual 457, who was HLA-A*0201
positive, made a similar CD81 T cell response (2.6%) to pep-
tides 8.4 (WWEEGRMTENIVEVA) and 8.5 (RMTENIVEVA-
KAVLG). The overlapping portion of these 2 peptides contained
the HLA-A*0201 anchor residues methionine at P2 and valine at
P9 [32], and the epitope RMTENIVEV scored highly using
binding algorithms (see Methods). This peptide was synthesized
and tested in functional assays. Figure 4 (bottom panel) shows
that this peptide triggers strong production of IFN-c. Thus this
epitope was synthesized on 2 separate occasions: first as a 15mer
and second as a 9mer, both triggering T cell responses. No other
individual was found to respond to this peptide.
To further quantify and phenotype the T cell response to the
RMTENIVEV epitope, a fluorescent-labeled tetrameric HLA-
A*0201–peptide complex (HLA-A*0201-RMT tetramer) was
synthesized and used to stain the PBMC of individual 457.
Staining revealed that .19% of peripheral CD81 T cells (or .06%
of CD31 cells) specifically recognized this epitope ex vivo
(Figure 5A, left panels). Ex vivo cells were stained for CCR7 and
CD45RA to identify their memory phenotype. As shown in
Figure 5A (middle and right panels), cells stained with HLA-
A*0201-RMT tetramer in this individual were CCR7 and
CD45RA negative, suggesting that they are effector memory
T cells. After in vitro culture with peptide for 10 days and 6
weeks, 7.0% of CD81 T cells were antigen specific (Figure 5B,
left and middle panels). A second sample taken 20 months after
the first was cultured for 23 days, and antigen-specific cells were
still detected (.17% of CD81 T cells [Figure 5B, right panels]).
This provides evidence that the cells were maintained over time
in vivo and were able to proliferate in culture.
DISCUSSION
We detected strong T cell responses to PARV4 NS in 23/88
HCV-positive individuals (26%) and in 3/13 HIV-positive in-
dividuals, 2 cohorts of individuals exposed to blood-borne vi-
ruses. These data suggest that PARV4 infections are relatively
common in these clinical groups and that viral antigen persists
to trigger andmaintain these responses.We also identify the first
(HLA-A*0201–restricted) PARV4 peptide epitope, RMTENI-
VEV, and show that CD81 T cells specific for this epitope in one
individual have an effector memory phenotype. The T cell re-
sponses are PARV4 specific, as there were no T cell responses to
PARV4 NS in healthy individuals or in acute B19 seroconverters.
Up to 60% of the adult population has been exposed to B19
[33], and our data therefore exclude the possibility of antigenic
cross-reactivity with B19 parvovirus. Cross-reactivity with HCV
is unlikely for several reasons. Responses were detected in an
HCV-negative HIV-positive group; the key epitope, RMTENI-
VEV, does not have a clear homologue in HCV; T cell responses
to HCV-derived peptides in this patient group with persistent
HCV infection are of extremely low frequency [34]. Addition-
ally, there is a strong association between PARV4 serostatus and
PARV4 T cell response (see Results).
The strong T cell responses reached 2000 SFU/million PBMCs
to a single 15mer peptide; thus PARV4 appears to be highly
immunogenic, at least in certain individuals. These T cell levels
are comparable to other low-load persistent viruses such as cy-
tomegalovirus (CMV) [35] and Epstein-Barr virus (EBV) [36].
Most of the responses were concentrated at the N-terminus of
the NS protein in both HCV-positive and HIV-positive cohorts.
This protein is poorly characterized functionally, although it
contains 2 known motifs: a rolling circle replication motif,
found at the N-terminus, and an adenosine triphosphatase do-
main [11, 37, 38]. The latter was represented in pool 7 of the NS
peptides and was shown to frequently elicit T cell responses.
Within the N-terminus of the NS protein there was no im-
munodominant epitope.
T cell responses were found at a similar frequency to that
previously found for PARV4 antibodies (33%) [18] and for
PARV4 DNA (30%) [21] in other HCV-positive individuals.
There was no relationship found between immune reactivity to
PARV4 and age (Mann-Whitney, P5 .71; Supplementary Table).
Parvovirus B19 has been shown to persist at very low levels in
bone marrow, skin, and synovia [39–41]. PARV4 may behave in a
similar manner, having been detected in autopsy tissue or at very
low viral load in tissue without viremia [4]. The T cell responses
observed against PARV4 were sustained for periods up to 3 years,
similar to that observed for T cell responses to parvovirus B19
[42]. This continuity supports the hypothesis that PARV4 is in-
deed a low-level persistent virus, providing a continuous supply
of antigen to stimulate CD81 T cells. PARV4-specific CD81
T cells have an effector memory phenotype (CCR7–CD45RA–
Figure 3. T cell responses to PARV4 NS protein in HIV-infected
individuals. Results are displayed as in Figures 1E–1F. Three of 13 HIV-
positive patients had a positive response to PARV4 NS peptide pools
(N067, N090, and R010, with CD41 T cell counts of 430, 350, and 460
cells/lL, respectively), and the distribution of responses across the NS
protein is shown. Individuals with no responses had CD41 T cell counts
between 130 and 1300 cells/lL (median: 430 cells/lL).
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[Figure 5]), suggesting recurrent antigen exposure as seen in CMV
[43, 44]. The study of HIV-positive individuals shows that T cell
responses to PARV4 NS are detectable even in individuals with a
degree of immune suppression (average CD41 T cell count of the
3 responders was 410 cells/lL).
Of the 84 HCV-positive individuals tested in both assays, and
21 with T cell responses to PARV4, only 14 also had antibodies to
PARV4. Moreover, 8 more individuals had antibodies to PARV4,
with no T cell responses. There could be several reasons for this.
First, the detection thresholds of the 2 assays are not directly
comparable, as one detects circulating antibody and the other,
individual cytokine-secreting cells, associated with different sen-
sitivities. The lack of IgM in individuals lacking IgG suggests that
they were not acutely infected. There may be an issue of differ-
ential specificity, since the ELISpot assay identifies immune re-
sponses to the PARV4 NS protein, whereas the ELISA detects
antibodies to PARV4 VP protein. As VP is a capsid protein, it is
expected that it would be a primary target for antibodies, whereas
CD81 T cells may preferentially recognize the NS protein, once
expressed intracellularly. So, potentially, where there is antibody
but no T cells detected, this may indicate induction of VP-specific
T cells rather than NS-specific T cells. A similar phenomenon has
been reported for parvovirus B19 [45, 46]. Further T cell studies
using VP peptides are in progress to address this issue.
Both assays look at the peripheral blood T cells in individuals.
While antibodies may be freely circulating, it is possible that
T cells activated by PARV4 are compartmentalized to tissues, as
seen in CMV, EBV, and HCV infections where CD81 T cells are
enriched in the liver [47]. Notably, PARV4 DNA has also been
found in the liver, among other tissues [3–5]. The lack of VP-
specific antibodies is surprising but was consistent as both assays
were repeated for several individuals at multiple time points.
There may have been a loss of circulating antibody over time, as
occurs with HCV after spontaneous control, where T cells may
be detected over longer periods [48]—sensitive analysis of an-
tigen-specific memory B cells might reveal low-frequency pop-
ulations, as we have previously described after hepatitis B virus
vaccination [49]. Maintenance of T cell responses in such
Figure 4. Demonstration of PARV4 NS peptides triggering the production of IFN-c by CD81 T cells. Short-term PBMC lines for patients 314 (upper
panel) and 457 (lower panel) elicit a CD81 T cell response to 2 pools of peptides and one 9mer epitope, respectively. The control peptide is a tetanus toxin
peptide [31].
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Figure 5. HLA-A*0201–restricted PARV4 RMTENIVEV-specific T cells have an effector memory phenotype and proliferate in culture in vitro. (A) FACS
plots for patient 457 (top panel), from whom the epitope was determined (HLA-A*0201 and positive response for peptides 8.4–8.5), and for patient 277
(lower panel, ''negative'' 5 no response on ELISpot assays to PARV4 NS). Left-hand plots are gated on CD31 cells. The middle and right-hand panels
assess the phenotype of the epitope-specific cells and are gated on CD31 CD81 T cells. CD45RA and CCR7 are used as memory markers. Antigen-specific
cells are visible in patient 457 at a frequency of .19% and do not present CD45RA or CCR7 on their surface. (B) After short-term culture, tetramer HLA-
A*02-RMT–positive cells have expanded to 7% of CD81 T cells. This appears to plateau as the level is unchanged after 6 weeks (middle panels).
Tetramer-positive cells are still visible at a second time point (right panels) in the same patient, although the percentage decreases. Samples from time
points 1 and 2 were taken 20 months apart.
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seronegative persons might then reflect low-level persistence of
antigen in tissue or potentially continued limited transcription
of NS—analogous to the setting in CMV infection [50]. Anti-
genic variation within parvoviruses resulting from distinct cir-
culating genotypes may also impact on the sensitivity of both
assays, although this should be limited as there is minimal
amino acid sequence variability among the 3 genotypes [10].
Planned experiments on longitudinal samples will allow us to
look at any changes in antibody levels and T cell responses. In
this study, no polymerase chain reaction tests for DNA were
carried out, as previous studies in comparable cohorts revealed
that DNA was only detected at very low frequency in peripheral
blood [3, 4, 8].
Parenteral infection appears to be the principal route of
transmission without being exclusive, as viral DNA has been
found in a small percentage of healthy adults [13–20], in
healthy infants in Ghana [9], and in HIV-positive individuals
who had no history of parenteral exposure [10]. A recent
study has also reported that up to 37% of the general pop-
ulation in some countries in Central Africa are seropositive
for PARV4, suggesting additional transmission routes [22].
The safety of blood products administered to vulnerable
populations warrants further investigation into this blood-
borne agent. So far, there is no clear link between PARV4
infection and disease, largely complicated by the burden of
disease in HCV- and HIV-infected individuals. Exploring the
role of T cells in unconventional persistent viral infections
such as B19 or PARV4 will contribute to the understanding of
the antiviral immune response.
This study is the first to identify T cell responses and to define
a CD81 T cell epitope for the novel parvovirus PARV4. Until
recently this virus was only detected by looking for viral DNA.
Through the availability of serological assays [18] and now T cell
assays, the prevalence of PARV4 in different populations and its
effect on the immune system can be more readily assessed.
Supplementary Data
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